Diese Präsentation wurde erfolgreich gemeldet.
Wir verwenden Ihre LinkedIn Profilangaben und Informationen zu Ihren Aktivitäten, um Anzeigen zu personalisieren und Ihnen relevantere Inhalte anzuzeigen. Sie können Ihre Anzeigeneinstellungen jederzeit ändern.

Hrt journal club

594 Aufrufe

Veröffentlicht am

Veröffentlicht in: Gesundheit & Medizin
  • Als Erste(r) kommentieren

  • Gehören Sie zu den Ersten, denen das gefällt!

Hrt journal club

  1. 1. Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. Dr J Romain ( BMJ 4.8.2007 335:239-244)
  2. 2. Introduction <ul><li>The use of HRT to control moderate to severe menopausal symptoms is well established. </li></ul><ul><li>Long term use for disease prevention in postmenopausal women is in dispute. </li></ul>
  3. 3. 1997 US Women’s Health Initiative Study <ul><li>Assessed prevention of cardiovascular disease in women 50-79yrs on HRT. </li></ul><ul><li>On combined HRT; </li></ul><ul><li>- Increased risk of stroke, PE, breast cancer and coronary events in elderly (70-79 yrs). </li></ul><ul><li>- Decreased risk of hip fracture, colon Ca </li></ul><ul><li>when compared to women taking placebo. </li></ul><ul><li>Oestrogen only; increased risk of stroke </li></ul><ul><li>Risks largely outweighed benefits </li></ul>
  4. 4. WISDOM <ul><li>Began recruiting 1999; UK, Aus and NZ </li></ul><ul><li>Designed to assess the balance of long term risks and benefits of hormone replacement therapy (combined vs placebo and oestrogen vs combined) </li></ul><ul><li>Aim for particular emphasis on cardiovascular disease and dementia </li></ul>
  5. 5. Participants <ul><li>Recruiting in general practice </li></ul><ul><li>Postmenopausal women aged 50-69 yrs, oldest women first </li></ul><ul><li>Main exclusion criteria; </li></ul><ul><li>-Hx breast or other Ca, endometrial probs, IHD, CVA/TIA’s, HRT within last 6 months </li></ul><ul><li>Randomised to conjugated equine oestrogen alone (hysterectomy patients) or that and medroxyprogesterone acetate </li></ul><ul><li>Aim for 10yrs treatment, ideally double-blind but vaginal bleeding triggered investigation </li></ul>
  6. 6. Data collection <ul><li>12 week run-in period. 80% compliance cut-off </li></ul><ul><li>Seen at 4, 14, 27, 40, 52 weeks, then 6/12 </li></ul><ul><li>Information collected on all outcomes, adverse events, and other medical history to check that patients remained eligible. </li></ul>
  7. 7. Outcome Measures <ul><li>Primary Outcomes </li></ul><ul><li>- major cardiovascular disease </li></ul><ul><li>- osteoporotic fractures </li></ul><ul><li>- breast cancer </li></ul><ul><li>Secondary Outcomes </li></ul><ul><li>- breast cancer mortality, other cancers </li></ul><ul><li>- venous thromboembolism </li></ul><ul><li>- cerebrovascular disease </li></ul><ul><li>- dementia </li></ul>
  8. 8. Sample Size <ul><li>Ideally 22,300. Provided 80% power at 5% significance to detect 29% reduction from an expected probability of a primary outcome event in the placebo group </li></ul><ul><li>Also power to detect; </li></ul><ul><li>- 20% reduction in all osteoporotic fractures </li></ul><ul><li>- 40% increase in breast cancer </li></ul>
  9. 9. Statistical Method <ul><li>Intention-to-treat principle when assessing treatment effects, with P<0.05 used to define statistical significance </li></ul><ul><li>To account for the prospective nature of the data, event rates were calculated (per 10 000 women-years) as the number of events divided by the relevant accumulated person-time </li></ul><ul><li>The results are reported as, respectively, rates and hazard ratios for the effect of combined therapy versus either placebo or oestrogen therapy (with 95% confidence intervals), with associated likelihood ratio tests for significance </li></ul>
  10. 10. Results <ul><li>226,282 women were eligible </li></ul><ul><li>Trial closed early in Oct 2002 due to publication of results from womens health initiative study- 155,204 women invited by this time </li></ul><ul><li>56,583 attended, 14,203 agreed to enter and 8980 entered at time of closure. </li></ul><ul><li>At end of run-in 5692 started trial </li></ul><ul><li>Mean age 62.8 yrs </li></ul><ul><li>Average of 15 years post menopause </li></ul><ul><li>Baseline characteristics similar in each group (% of women prev using HRT etc.) </li></ul>
  11. 11. Results <ul><li>Due to early closure follow up median of 11.9 months </li></ul><ul><li>Total 6498 women years </li></ul><ul><li>Clinical Outcomes; </li></ul><ul><li>- total number of events low due to early closure </li></ul><ul><li>- no data on dementia as first follow-up due after 2 years </li></ul>
  12. 12. Combined VS Placebo <ul><li>Significantly increased rates of cardiovascular events (P=0.016) and VTE in combined group (P=<0.001) </li></ul><ul><li>-all but 2 women over 64yrs </li></ul><ul><li>-all had 1 or more cardiovascular risks </li></ul><ul><li>Non significant reduction in rates of oseoporotic fractures (P=0.07) </li></ul><ul><li>Rates of cerebrovascular disease, breast cancer and other cancers did not differ. </li></ul>
  13. 13. Combined VS Oestrogen Alone <ul><li>Numbers a lot smaller in this group; n=1641 compared to n=4385 </li></ul><ul><li>Suggestion in combined group of increase in cardiovascular events (P=0.40) and VTE (P=0.19) </li></ul>
  14. 14. Adverse Events <ul><li>15 deaths during trial </li></ul><ul><li>Non-significant increase in combined group compared with placebo </li></ul><ul><li>No excess of serious adverse events in either of the randomised comparisons. </li></ul>
  15. 15. Discussion <ul><li>Data suggests that women starting or restarting combined oestrogen and progestogen therapy an average of 15 years after menopause are at increased risk of cardiovascular disease and venous thromboembolism, at least in the early years of treatment </li></ul><ul><li>Trend towards a decreased risk of osteoporotic fracture </li></ul>
  16. 16. Discussion <ul><li>Results for early cardiovascular and thromboembolic disease; </li></ul><ul><ul><li>oestrogen only therapy may have similar, but smaller, short term effects compared to combined </li></ul></ul><ul><ul><li>results consistent with the findings of the combined therapy arm of the women's health initiative study </li></ul></ul><ul><ul><li>Supports conclusion that combined therapy should not be given for cardiovascular disease prevention in older postmenopausal women </li></ul></ul>
  17. 17. Discussion <ul><li>Early increased risk of cardiovascular events in BOTH trials is compatible with the hypothesis that administration of hormone replacement therapy, particularly combined oestrogen and progestogen therapy, to women many years after menopause, who are likely to have established atherosclerosis, may cause disruption of the plaque surface, with subsequent platelet adhesion, clotting, and further arterial narrowing. </li></ul>
  18. 18. Value of Study <ul><li>Contribution to the body of knowledge about hormone replacement therapy started in older postmenopausal women of a mean age of 63 years </li></ul><ul><li>participants are likely to be representative of the general population of women of this age and the results applicable to this older age group </li></ul><ul><li>Limitations- early closure and therefore reduced recruitment and power. Few women in younger age groups. Only two types of HRT assessed. </li></ul>
  19. 19. Discussion <ul><li>results of WISDOM, help test the hypothesis that starting long term hormone replacement therapy in elderly, often asymptomatic, women in their 60s might reduce major morbidities, in particular cardiovascular disease. This does NOT seem likely. </li></ul><ul><li>Currently it is rare to start taking therapy at this age </li></ul>
  20. 20. Conclusions <ul><li>Cannot draw conclusions for women taking HRT around time of menopause </li></ul><ul><li>However there may be no increased benefit, and indeed some risk, for women commencing HRT many years after menopause for few or no menopausal symptoms. </li></ul><ul><li>If there is a ‘window’ of benefit this is likely to vary with arterial risk factors and obesity </li></ul>
  21. 21. <ul><li>THE END! </li></ul>